These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

559 related articles for article (PubMed ID: 35354425)

  • 41. Don't blame the messenger: lessons learned for cancer mRNA vaccines during the COVID-19 pandemic.
    Morris VK; Kopetz S
    Nat Rev Cancer; 2022 Jun; 22(6):317-318. PubMed ID: 35277674
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Clinical advances and ongoing trials on mRNA vaccines for cancer treatment.
    Lorentzen CL; Haanen JB; Met Ö; Svane IM
    Lancet Oncol; 2022 Oct; 23(10):e450-e458. PubMed ID: 36174631
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Messenger RNA-based vaccines: Past, present, and future directions in the context of the COVID-19 pandemic.
    Jain S; Venkataraman A; Wechsler ME; Peppas NA
    Adv Drug Deliv Rev; 2021 Dec; 179():114000. PubMed ID: 34637846
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A Comprehensive Review of mRNA Vaccines.
    Gote V; Bolla PK; Kommineni N; Butreddy A; Nukala PK; Palakurthi SS; Khan W
    Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36769023
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Can the triumph of mRNA vaccines against COVID-19 be extended to other viral infections of humans and domesticated animals?
    Sehrawat S; Osterrieder N; Schmid DS; Rouse BT
    Microbes Infect; 2023; 25(1-2):105078. PubMed ID: 36435367
    [TBL] [Abstract][Full Text] [Related]  

  • 46. mRNA Vaccine Development for Emerging Animal and Zoonotic Diseases.
    Le T; Sun C; Chang J; Zhang G; Yin X
    Viruses; 2022 Feb; 14(2):. PubMed ID: 35215994
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Self-assembled mRNA vaccines.
    Kim J; Eygeris Y; Gupta M; Sahay G
    Adv Drug Deliv Rev; 2021 Mar; 170():83-112. PubMed ID: 33400957
    [TBL] [Abstract][Full Text] [Related]  

  • 48. COVID-19 vaccine development during pandemic: gap analysis, opportunities, and impact on future emerging infectious disease development strategies.
    Rele S
    Hum Vaccin Immunother; 2021 Apr; 17(4):1122-1127. PubMed ID: 32993453
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clinical approval of nanotechnology-based SARS-CoV-2 mRNA vaccines: impact on translational nanomedicine.
    Milane L; Amiji M
    Drug Deliv Transl Res; 2021 Aug; 11(4):1309-1315. PubMed ID: 33512669
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Delivery Strategies for mRNA Vaccines.
    Ramachandran S; Satapathy SR; Dutta T
    Pharmaceut Med; 2022 Feb; 36(1):11-20. PubMed ID: 35094366
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Sequence-Optimized mRNA Vaccines Against Infectious Disease.
    Rauch S; Lutz J; Mühe J; Kowalczyk A; Schlake T; Heidenreich R
    Methods Mol Biol; 2024; 2786():183-203. PubMed ID: 38814395
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The mRNA Revolution is Coming.
    Bates M
    IEEE Pulse; 2021; 12(6):2-5. PubMed ID: 34968173
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Advancing mRNA technologies for therapies and vaccines: An African context.
    Kairuz D; Samudh N; Ely A; Arbuthnot P; Bloom K
    Front Immunol; 2022; 13():1018961. PubMed ID: 36353641
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Current state of, prospects for, and obstacles to mRNA vaccine development.
    Aljabali AAA; Bashatwah RM; Obeid MA; Mishra V; Mishra Y; Serrano-Aroca Á; Lundstrom K; Tambuwala MM
    Drug Discov Today; 2023 Feb; 28(2):103458. PubMed ID: 36427779
    [TBL] [Abstract][Full Text] [Related]  

  • 55. mRNA vaccine: a potential therapeutic strategy.
    Wang Y; Zhang Z; Luo J; Han X; Wei Y; Wei X
    Mol Cancer; 2021 Feb; 20(1):33. PubMed ID: 33593376
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Advancements of in vitro transcribed mRNA (IVT mRNA) to enable translation into the clinics.
    Kang DD; Li H; Dong Y
    Adv Drug Deliv Rev; 2023 Aug; 199():114961. PubMed ID: 37321375
    [TBL] [Abstract][Full Text] [Related]  

  • 57. mRNA vaccines manufacturing: Challenges and bottlenecks.
    Rosa SS; Prazeres DMF; Azevedo AM; Marques MPC
    Vaccine; 2021 Apr; 39(16):2190-2200. PubMed ID: 33771389
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Messenger RNA-Based Vaccines Against Infectious Diseases.
    Alameh MG; Weissman D; Pardi N
    Curr Top Microbiol Immunol; 2022; 440():111-145. PubMed ID: 32300916
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Research Advances on the Stability of mRNA Vaccines.
    Cheng F; Wang Y; Bai Y; Liang Z; Mao Q; Liu D; Wu X; Xu M
    Viruses; 2023 Mar; 15(3):. PubMed ID: 36992377
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Emerging trends of research on mRNA vaccines: A co-citation analysis.
    Chen J; Zhang T; Lu Y; Yang X; Ouyang Z
    Hum Vaccin Immunother; 2022 Nov; 18(6):2110409. PubMed ID: 36018287
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.